Alluvi, previously BI 4744, represents a significant breakthrough in obesity therapy. This dual activator targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide sites demonstrates https://alluvi944520.keablog.com/61821280/alluvi-a-detailed-investigation-into-the-drug-s-possibilities